Trial Profile
Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant; Tamoxifen
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 06 Aug 2019 Status changed from active, no longer recruiting to completed.
- 27 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
- 22 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.